Clinical trials: Depression Moderate
Treatment Resistant Depression
KET-RO Plus RO DBT for Treatment Resistant Depression
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD).
- Trial name
- KET-RO (NCT06138691)
- Testing
- Ketamine Infusion plus RO DBT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Depressive Symptoms, Quality of Life
Testing TRUST Depression Management Intervention
This study evaluates the effectiveness of a novel depression self-management intervention in adolescents with depression.
- Trial name
- TRUST (NCT03599141)
- Testing
- Trust-building Self-management Together, Depression Management
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Case Western Reserve University
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-2 (NCT05550532)
- Testing
- Aticaprant
- Where
- 131 sites in United States, Argentina and 12 more
- Volunteers
- 444 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-1 (NCT05455684)
- Testing
- Aticaprant
- Where
- 120 sites in United States, Argentina and 11 more
- Volunteers
- 513 people
- Sponsor
- Janssen Research & Development, LLC
Infant, Newborn, Hypoxia, Brain
Preemie Hypothermia for Neonatal Encephalopathy
This study is a randomized, controlled trial to assess safety and effectiveness of whole body hypothermia for 72 hours in preterm infants 33-35 weeks gestational age (GA) who present at <6 hours postnatal age with moderate to…
- Conditions
- Infant, Newborn, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Encephalopathy, Hypoxic-Ischemic
- Trial name
- NCT01793129
- Testing
- Hypothermia, Normothermic Control
- Where
- 18 sites in United States
- Volunteers
- 168 people
- Sponsor
- NICHD Neonatal Research Network
Major Depressive Disorder
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
The overall objective of this trial is to demonstrate clinically relevant superior antidepressant efficacy of the fixed dose combination PNB01 (low dose pipamperone and citalopram) over reference antidepressant treatment with…
- Trial name
- NCT01312922
- Testing
- PNB01 fixed dose combination of pipamperone and citalopram, Citalopram, Pipamperone
- Where
- 31 sites in United States, Canada
- Volunteers
- 555 people
- Sponsor
- PharmaNeuroBoost N.V.
Severe Asthma, Moderate or Severe Major Depressive Disorder
Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder
The purpose is to determine if: 1) Escitalopram treatment will be associated with less oral corticosteroid use than placebo in outpatients with severe asthma and moderate or severe major depressive disorder (MDD).
- Trial name
- NCT00621946
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depression
A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder
This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in 102 participants diagnosed with moderate to severe Major Depressive Disorder.
- Trial name
- NCT03000530
- Testing
- SAGE-217
- Where
- 8 sites in United States
- Volunteers
- 102 people
- Sponsor
- Biogen
Depression, Anxiety Disorders
Investigating Transcranial Ultrasound as a Potential Intervention for Depression
Depression is the leading cause of disability worldwide. Because a significant number of people with depression do not respond to medication or therapy, alternative treatment options are greatly needed.
- Trial name
- NCT02685488
- Testing
- Transcranial Ultrasound Power
- Volunteers
- 26 people
- Sponsor
- University of Arizona
Stress Disorders, Traumatic, Stress Disorders, Traumatic, Acute
Researching Resiliency in Stressful Experiences (RISE) Program for Men Leaving Incarceration
The investigators are conducting a randomized controlled trial to assess the impact of Resiliency in Stressful Experiences (RISE) - a comprehensive trauma-based program for young men releasing from a southeastern state's prisons.
- Conditions
- Stress Disorders, Traumatic, Stress Disorders, Traumatic, Acute, Depressive Symptoms, Anxiety
- Trial name
- NCT04785677
- Testing
- Resiliency in Stressful Experiences (RISE) Program
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Florida State University
Moderate Depression, Menopausal and Postmenopausal Disorders
Homeopathic Treatment for Depression in Peri- and Postmenopausal Women
The aim of this study was to determine whether individualized homeopathic treatment and fluoxetine are more efficient than placebo for moderate to severe depression in peri- and postmenopausal women.
- Trial name
- HOMDEP-MENOP (NCT01635218)
- Testing
- Individualized homeopathic treatment, Fluoxetine
- Where
- Mexico
- Volunteers
- 133 people
- Sponsor
- Hospital Juarez de Mexico
Postpartum Depression
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 micrograms per kilogram per hour (μg/kg/h) for 60 hours reduces depressive symptoms in participants with severe postpartum…
- Trial name
- NCT02942004
- Testing
- SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 138 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Postpartum Depression
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo…
- Trial name
- NCT02942017
- Testing
- SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Spinal Cord Injury
Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury
This study was initially designed to test the efficacy of Venlafaxine HCl in reducing incidence of the onset of major depression after a new spinal cord injury (SCI).
- Trial name
- NCT00735670
- Testing
- Venlafaxine HCl
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Michigan
Major Depressive Disorder
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
This is an open-label, parallel-group study to evaluate the safety and efficacy of Ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
- Trial name
- NCT06126497
- Testing
- Ropanicant
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Suven Life Sciences Limited
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Depression, Relapsing-remitting Multiple Sclerosis
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
This is a prospective, multi-center, open-label study in Relapsing-remitting Multiple Sclerosis (RRMS) patients with mild to moderate depression treated with selected serotonin reuptake inhibitors (SSRI) or serotonin and…
- Trial name
- REGAIN (NCT01436643)
- Testing
- Venlafaxine, Fluoxetine, Citalopram
- Where
- 25 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Pain, Respiratory Depression
Study of Respiratory Depression When Using a Hydromorphone Pain Protocol
This is a study about the efficiency and safety of a 1mg+1mg hydromorphone pain management protocol for the treatment of moderate to sever pain in the Emergency Department.
- Trial name
- NCT01784991
- Testing
- Hydromorphone, Usual care group
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Albert Einstein Healthcare Network
Postpartum Depression
[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]
This study evaluates the efficacy of two digital therapeutics, WB001 and ED001, on depressive symptoms among women diagnosed with postpartum depression.
- Trial name
- NCT05551195
- Testing
- WB001, ED001
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Woebot Health